Purpose of review Epstein-Barr virus (EBV) reactivation can cause significant morbidity and mortality after allogeneic hematopoietic stem cell transplant. Delays in reconstitution of EBV-specific T lymphocyte activity can lead to life-threatening EBV lymphoproliferative disease (EBV-PTLD). This review highlights recent advances in the understanding of pathophysiology, risk factors, diagnosis, and management of EBV viremia and PTLD.
INTRODUCTION
Epstein-Barr virus (EBV) is a highly immunogenic latent g-herpesvirus that has infected more than 90% of humans worldwide. During a primary infection, a normal host will mount a vigorous CD4 þ and CD8 þ cellular immune response, and these T cells should control both the primary infection and any periodic EBV reactivations [1] . However, EBV reactivation can cause significant morbidity and mortality in immunocompromised recipients after allogeneic hematopoietic stem cell transplantation (HSCT). Delays in reconstitution of EBV-specific T lymphocyte activity can lead to fulminant viremia and progress to life-threatening EBV lymphoproliferative disease (EBV-PTLD).
PATHOPHYSIOLOGY AND CLINICAL PRESENTATION
PTLD after HSCT is predominantly derived from donor B cells and typically occurs within the first 6 months after HSCT, before reconstitution of the EBV cytotoxic T lymphocyte (EBV-CTL) response [1] . PTLD usually presents as lymphadenopathy or discrete lesions, although it may manifest as a diffuse process that mimics fulminant sepsis syndrome [2, 3] .
RISK FACTORS AND DIAGNOSIS
Although the incidence of EBV-PTLD is generally lower than 2% and has not changed in recent years, it may increase to 10-20% in patients with established risk factors [4 EBV-viremia and PTLD are related to T cell depletion of the graft, the degree of donor-recipient mismatch, and the extent of immunosuppression used to prevent and/or treat graft-versus-host disease (GVHD) [5 & ]. Initial studies in recipients who received a T cell-depleted graft found that an elevated EBV-DNA load was highly predictive of EBV-PTLD [6, 7] . However, follow-up studies including a broader range of HSCT recipients have shown that only 50% of patients with an EBV-DNA level greater than 4000 copies/mg subsequently developed PTLD [8] . Nevertheless, recent evidence-based guidelines from the European Conference in Infections in Leukemia recommend weekly screening of EBV-DNA for at least 3 months in high-risk allogeneic HSCT recipients [9] . Further, although proliferating B cells are almost always of donor origin, recent reports described a high incidence of PTLD in pediatric patients who received reduced intensity conditioning (RIC) regimens utilizing antithymocyte globulin (ATG) or alemtuzumab that may be secondary to persisting recipient-derived B cells [10, 11] .
EBV-PTLD may evolve from a polyclonal disorder to a more aggressive monoclonal variant; therefore, early diagnosis and prompt treatment is key. Algorithms have been developed to identify patients who may benefit from early intervention [1] . However, as discussed above, measurement of EBV load by quantitative PCR (QPCR) can be sensitive enough for diagnosis but not always sufficiently specific enough to determine onset of disease. Moreover, in some cases, viral loads remain below conventionally accepted thresholds for preemptive therapy at symptomatic presentation. These observations illustrate the limitations of preemptive paradigms that rely only on viral load to predict PTLD [ þ T lymphocyte counts greater than 50/ml at day þ30 were significantly associated with a reduced risk of high-load EBV-DNAemia (>10 000 copies/ml), and therefore decreased risk of PTLD development.
EBV reactivation, although not a frequent occurrence, remains a problem after umbilical cord blood transplantation (UCBT). Dumas et al. [ 13 & ] retrospectively studied EBV levels, using QPCR, during the first 3 months after UCBT in 175 patients. Twenty-four patients presented with EBV reactivation, of whom four had EBV-PTLD. More than 60% (15/24) developed reactivation during the first 100 days after transplant. The authors noted that early EBV reactivation was associated with RIC in combination with ATG (P ¼ 0.03) and a previous history of auto-HSCT (
analyzed the incidence of EBV-PTLD in 288 adult UCBT recipients. Twelve patients developed PTLD at a median of 73 days. All patients presented with extranodal involvement (visceral and central nervous system) confirmed to be of donor origin. Overall, the prognosis was poor despite routine viral monitoring and early intervention, as EBV-PTLD was the cause of death in 11 patients who had a median time to death of 23 days after diagnosis. In their cohort, the 3-year cumulative incidence of EBV-PTLD was significantly higher among recipients of RIC vs. myeloablative regimens (12.9 and 2.6%, respectively, P < 0.0001) [ Although rituximab has undoubtedly improved the outcome for SCT-PTLD, it remains ineffective for a significant proportion of patients.
The availability of more rapid EBV-specific T cell products offers the possibility of improved outcomes.
potentially reduce the risk of developing EBV-associated lymphoma [15 && ].
TREATMENT
Despite identification of patients at increased risk for EBV, determination of when and how to initiate preemptive therapy remains challenging. Therapeutic options to treat EBV viremia and PTLD include B cell depletion of the graft, post-stem cell transplantation (SCT) restoration of the immune response to EBV, and targeting pathogenic B cells.
B cell depletion with rituximab
One preemptive strategy for reducing the risk associated with EBV and PTLD involves administration of rituximab as either part of the conditioning regimen, or post-SCT to reduce EBV reactivations. Dominietto
] performed a retrospective analysis in 55 patients who received a fixed dose of rituximab on day þ5 post allogeneic SCT to prevent development of EBV viremia. When compared with 68 controls who did not receive preemptive rituximab, patients had significantly lower rates of EBV-DNA levels (56 vs. 85%, P ¼ 0.0004), a lower number of maximum EBV copies (91 vs. 1321/10 5 cells, P ¼ 0.003), and significantly reduced cumulative incidence of grade II-IV acute GVHD (aGVHD)
developed a preemptive intervention protocol based on duration and changes in EBV viral load. EBV-DNA levels were monitored by QPCR in 251 allogeneic SCT recipients. When EBV-DNA was detected in the blood of two consecutive samples, the patients began antiviral therapy and reduced immunosuppression, if feasible. If EBV-DNA levels continued to rise, the second step included administration of rituximab (375 mg/m 2 ) weekly until EBV-DNA was undetectable or for up to 4 weeks. Of 64 patients treated with the first-step, 24 (37.5%) achieved a complete response. The remaining 40 had no response, with 25 of those developing an EBV-associated disease. The effective response rates of antiviral agents or reduced immunosuppression plus antiviral agents were two out of 16 and 22 out of 48 (P ¼ 0.017), respectively. Of 15 patients who required rituximab, 14 achieved a complete response. These findings suggest that reduced immunosuppression plus antiviral agents is a reasonable initial strategy, whereas more frequent monitoring of EBV-DNA and earlier preemptive rituximab should be advocated in high-risk patients [ ]. These findings thus underscore the observation that although rituximab has undoubtedly improved the outcome for SCT-PTLD, it remains ineffective for a significant proportion of patients.
Adoptive immunotherapy
Adoptive immunotherapy with unmanipulated donor T cells and EBV-CTLs has provided well tolerated, effective, and long-term antiviral protection. Unmanipulated DLIs can reconstitute EBV-specific immunity and have clinical response rates from 60 to 90% [19] ; however, a recent review suggested that only 41% of patients with established disease achieve sustained complete responses [20] . Additionally, aGVHD is a well known complication of DLI, thus limiting its use. Doubrovina et al. [21 && ] evaluated HLA-compatible DLIs and HLA-compatible or disparate EBV-CTLs in 49 HSCT recipients with biopsy-proven EBV-lymphoproliferative disease, including those with rituximab-resistant disease. Of 30 patients primarily treated with DLI, 17 achieved a complete response and one a partial response for an overall response rate of 73%. Of patients primarily treated with EBV-CTLs, 68% achieved a sustained complete response with median follow-up of 80 months. As predicted, reversible aGVHD occurred in 17% of DLI recipients vs. zero who received EBV-CTLs. Overall, EBV-CTLp frequencies increased by 2 to 3 log within 7-14 days in responders with complete resolution of disease. , complete virologic responses were seen in 80% of patients (including two with EBV lymphoma and two with EBV reactivations), which is equivalent to that achieved in previous trials using more complex manufacturing. Recently, the T cell manufacturing process has been further simplified to use overlapping peptide pools as a source of antigen (derived from the EBNA1, latent membrane protein 2, and BZLF1 EBV antigens), and the response rate has been maintained with resolution of disease in two patients with EBV reactivation and two with EBV-PTLD 
Third-party Epstein-Barr virus-specific cytotoxic T lymphocytes
Although rapid manufacturing techniques improve availability of donor EBV-CTLs for clinical use, there is still need for an immediately accessible, or off-theshelf, source of effector cells. In addition, the above manufacturing methodologies cannot expand EBVCTLs from seronegative donors or cord blood. Therefore, much attention has been directed toward establishment of third-party donor banks based on partial HLA matching and appropriate HLA restriction. This approach was first tested in the clinic by Haque et al.
[26] who observed a 53% response rate at 6 months when the most closely matched thirdparty product was used in patients with refractory PTLD after HSCT or solid organ transplant.
In ] developed a system for the rapid generation of CTLs using selection of IFN-g-secreting EBV-CTLs followed by retroviral transduction with a calcineurin B mutant. With this methodology, highly specific EBV-CTLs resistant to the calcineurin inhibitor tacrolimus, and with negligible alloreactivity, were effectively produced in 14 days [29 && ].
Toxicity of Epstein-Barr virus-specific T cells
Clinically, there were no reported infusion-related adverse events, significant toxicity, or graft rejection attributable to CTL infusion, and only minimal denovo GVHD after adoptive transfer of the VSTs described above. However, Papadopoulou et al. 
CONCLUSION
Despite the development of early-interventionbased treatment guidelines, long-term survival of patients with PTLD remains suboptimal. Continued improvements in both risk stratification and alternative treatment options are required to improve the morbidity and mortality caused by EBV-associated diseases. The availability of more rapid EBV-specific T cell products offers the possibility of improved outcomes. In this study, the authors identified a CD4 þ T lymphocyte count greater than 50/ml at day þ30 as the only factor significantly associated with a reduced risk of highload EBV DNAemia. In this retrospective study of UCBT recipients, more than 60% of patients developed EBV reactivation during the first 100 days after transplant. Early EBV reactivation was associated with RIC in combination with ATG and a previous history of auto-HSCT. 14. In this study, a rapid approach using nucleofection and DNA plasmids was used to generate donor-derived trivirus-specific T cell lines over 2 to 3 weeks. In a clinical trial, complete virologic responses were seen in 80% of patients, equivalent to that achieved in previous trials using more complex manufacturing. 24.
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